Drugs

, Volume 65, Issue 4, pp 433–445 | Cite as

Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus

An Update
  • Marcel M. C. Hovens
  • Jouke T. Tamsma
  • Edith D. Beishuizen
  • Menno V. Huisman
Leading Article

Abstract

Morbidity and mortality in patients with type 2 diabetes mellitus is largely dominated by the occurrence of cardiovascular disease (CVD). Treatment of known risk factors of CVD has proven to be beneficial in terms of reduction in risk of major CVD events in the general population. Recent trials have provided information on the treatment of hyperglycaemia, hypertension, dyslipidaemia and platelet aggregation in the patient with type 2 diabetes.

Strict glycaemic control is not associated with a significant reduction in CVD risk, although new hypoglycaemic agents may offer additional benefits. In contrast, it has been demonstrated that treatment of hypertension and dyslipidaemia significantly reduce cardiovascular risk. Meticulous control of blood pressure to a level ≤130/80mm Hg, preferably using renin-angiotensin system-modulating agents, is of proven value. Use of HMG-CoA reductase inhibitors (statins) as low-density lipoprotein (LDL)-cholesterol-lowering therapy, initiated at a level of ≥2.60 mmol/L is firmly established. Recent trials lend support to lowering the target level for LDL-cholesterol-lowering therapy to <1.81 mmol/L. Mainly based on risk analogy, international guidelines advocate the use of aspirin (acetylsalicylic acid) in the primary prevention of CVD in patients with type 2 diabetes. However, there is no support from large trials that the estimated 25% risk reduction in primary prevention in a high-risk population is the same in the subgroup with diabetes.

An intensified approach in order to identify and treat cardiovascular risk factors in patients with type 2 diabetes, stratified to individual patients, is necessary to reduce the excess cardiovascular burden of these patients.

Keywords

Clopidogrel Atorvastatin Fenofibrate Ezetimibe Fibric Acid Derivative 

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047–53PubMedCrossRefGoogle Scholar
  2. 2.
    Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289(1): 76–9PubMedCrossRefGoogle Scholar
  3. 3.
    Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care 1998; 21(7): 1138–45PubMedCrossRefGoogle Scholar
  4. 4.
    Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2(2): 120–6PubMedCrossRefGoogle Scholar
  5. 5.
    Sprafka JM, Burke GL, Folsom AR, et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care 1991; 14(7): 537–43PubMedCrossRefGoogle Scholar
  6. 6.
    Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281(14): 1291–7PubMedCrossRefGoogle Scholar
  7. 7.
    Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109(4): 476–80PubMedCrossRefGoogle Scholar
  8. 8.
    Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229–34PubMedCrossRefGoogle Scholar
  9. 9.
    Lee CD, Folsom AR, Pankow JS, et al. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109(7): 855–60PubMedCrossRefGoogle Scholar
  10. 10.
    Cho E, Rimm EB, Stampfer MJ, et al. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 2002; 40(5): 954–60PubMedCrossRefGoogle Scholar
  11. 11.
    Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. Am J Med 2004; 117(2): 109–17PubMedCrossRefGoogle Scholar
  12. 12.
    Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 2000; 50(1): 1–16PubMedCrossRefGoogle Scholar
  13. 13.
    Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 2002; 90(5A): 19G–26GPubMedCrossRefGoogle Scholar
  14. 14.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 Suppl. 1: S15–35CrossRefGoogle Scholar
  15. 15.
    Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 383–93PubMedCrossRefGoogle Scholar
  16. 16.
    Yki-Jarvinen H. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs 2000; 60(5): 975–83PubMedCrossRefGoogle Scholar
  17. 17.
    Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263 (2 Pt 2): H321–6PubMedGoogle Scholar
  18. 18.
    McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35(8): 771–6PubMedGoogle Scholar
  19. 19.
    Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24(5): 816–23PubMedCrossRefGoogle Scholar
  20. 20.
    Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Nor-folk). BMJ 2001; 322(7277): 15–8PubMedCrossRefGoogle Scholar
  21. 21.
    Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22(2): 233–40PubMedCrossRefGoogle Scholar
  22. 22.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53Google Scholar
  23. 23.
    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 854–65Google Scholar
  24. 24.
    Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18 Suppl. 2: S10–5PubMedCrossRefGoogle Scholar
  25. 25.
    Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001; 21(12): 1891–5PubMedCrossRefGoogle Scholar
  26. 26.
    Dandona P, Aljada A. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. J Diabetes Complications 2004; 18(2): 91–102PubMedCrossRefGoogle Scholar
  27. 27.
    Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86(7): 3452–6PubMedCrossRefGoogle Scholar
  28. 28.
    Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am J Cardiol 2004; 93(11): 27C-31CCrossRefGoogle Scholar
  29. 29.
    Prisant LM. Clinical trials and lipid guidelines for type II diabetes. J Clin Pharmacol 2004; 44(4): 423–30PubMedCrossRefGoogle Scholar
  30. 30.
    National Institute of Diabetes and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States, 2003. Bethesda (MD): US Department of Health and Human Services, National Institutes of Health, 2004Google Scholar
  31. 31.
    Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334(1): 13–8PubMedCrossRefGoogle Scholar
  32. 32.
    Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16(2): 434–44PubMedCrossRefGoogle Scholar
  33. 33.
    Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276(23): 1886–92PubMedCrossRefGoogle Scholar
  34. 34.
    Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340(9): 677–84Google Scholar
  35. 35.
    Tight blood pressure control and risk of macro vascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317 (7160): 703–13Google Scholar
  36. 36.
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321(7258): 412–9PubMedCrossRefGoogle Scholar
  37. 37.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351(9118): 1755–62Google Scholar
  38. 38.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253–9CrossRefGoogle Scholar
  39. 39.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–72PubMedCrossRefGoogle Scholar
  40. 40.
    European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6): 1011–53CrossRefGoogle Scholar
  41. 41.
    Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36(3): 646–61Google Scholar
  42. 42.
    Jacoby D, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2004; 163: 1155–64CrossRefGoogle Scholar
  43. 43.
    Myata T, van Ypersele de Strihou C, Ueda Y. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478–87CrossRefGoogle Scholar
  44. 44.
    Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338(10): 645–52PubMedCrossRefGoogle Scholar
  45. 45.
    Pahor M, Tatti P. The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies. Am J Cardiol 1999; 83(5): 819–20PubMedCrossRefGoogle Scholar
  46. 46.
    Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24(12): 2091–6PubMedCrossRefGoogle Scholar
  47. 47.
    Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317 (7160): 713–20Google Scholar
  48. 48.
    Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 1004–10PubMedCrossRefGoogle Scholar
  49. 49.
    Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356(9227): 359–65PubMedCrossRefGoogle Scholar
  50. 50.
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356(9227): 366–72PubMedCrossRefGoogle Scholar
  51. 51.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981–97Google Scholar
  52. 52.
    Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354(9192): 1751–6PubMedCrossRefGoogle Scholar
  53. 53.
    Okada K, Hirano T, Ran J, et al. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 2004; 27(4): 293–9PubMedCrossRefGoogle Scholar
  54. 54.
    Anan F, Takahashi N, Ooie T, et al. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 2004; 53(6): 777–81PubMedCrossRefGoogle Scholar
  55. 55.
    Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care 2004; 27(1): 247–55PubMedCrossRefGoogle Scholar
  56. 56.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–60PubMedCrossRefGoogle Scholar
  57. 57.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–8PubMedCrossRefGoogle Scholar
  58. 58.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861–9PubMedCrossRefGoogle Scholar
  59. 59.
    Dusing R, Lehnert H. Diabetogenic effect of antihypertensive treatment: primum nil nocere. Nephrol Dial Transplant 2004; 19(3): 531–4PubMedCrossRefGoogle Scholar
  60. 60.
    Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: atherosclerosis risk in communities study. N Engl J Med 2000; 342(13): 905–12PubMedCrossRefGoogle Scholar
  61. 61.
    Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316(7134): 823–8PubMedCrossRefGoogle Scholar
  62. 62.
    Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27(6): 1496–504PubMedCrossRefGoogle Scholar
  63. 63.
    Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19(6): 540–56PubMedCrossRefGoogle Scholar
  64. 64.
    Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20(4): 614–20PubMedCrossRefGoogle Scholar
  65. 65.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level: cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335(14): 1001–9PubMedCrossRefGoogle Scholar
  66. 66.
    Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287(24): 3215–22PubMedCrossRefGoogle Scholar
  67. 67.
    Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140(8): 650–8PubMedGoogle Scholar
  68. 68.
    Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005–16PubMedCrossRefGoogle Scholar
  69. 69.
    Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288 (23): 2998–3007Google Scholar
  70. 70.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial —Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149–58PubMedCrossRefGoogle Scholar
  71. 71.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–504PubMedCrossRefGoogle Scholar
  72. 72.
    Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685–96PubMedCrossRefGoogle Scholar
  73. 73.
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227–39PubMedCrossRefGoogle Scholar
  74. 74.
    Feldman T, Koren M, Insull Jr W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93(12): 1481–6PubMedCrossRefGoogle Scholar
  75. 75.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317(20): 1237–45PubMedCrossRefGoogle Scholar
  76. 76.
    Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162(22): 2597–604PubMedCrossRefGoogle Scholar
  77. 77.
    Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357(9260): 905–910Google Scholar
  78. 78.
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71–86CrossRefGoogle Scholar
  79. 79.
    Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992; 268 (10): 1292–300Google Scholar
  80. 80.
    Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321(3): 129–35CrossRefGoogle Scholar
  81. 81.
    Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26(12): 3264–72PubMedCrossRefGoogle Scholar
  82. 82.
    Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90(6): 625–8PubMedCrossRefGoogle Scholar
  83. 83.
    Colwell JA. Aspirin therapy in diabetes. Diabetes Care 2004; 27 Suppl. 1: S72–3PubMedCrossRefGoogle Scholar
  84. 84.
    Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001; 24(2): 197–201PubMedCrossRefGoogle Scholar
  85. 85.
    Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85(3): 265–71PubMedCrossRefGoogle Scholar
  86. 86.
    Canizo-Gomez FJ, Moreira-Andres MN. Cardiovascular risk factors in patients with type 2 diabetes: do we follow the guidelines? Diabetes Res Clin Pract 2004; 65(2): 125–33PubMedCrossRefGoogle Scholar
  87. 87.
    George PB, Tobin KJ, Corpus RA, et al. Treatment of cardiac risk factors in diabetic patients: how well do we follow the guidelines? Am Heart J 2001; 142(5): 857–63PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Marcel M. C. Hovens
    • 1
  • Jouke T. Tamsma
    • 1
  • Edith D. Beishuizen
    • 1
  • Menno V. Huisman
    • 1
  1. 1.Department of General Internal MedicineLeiden University Medical CentreLeiden, C01-Rthe Netherlands

Personalised recommendations